Literature DB >> 18956645

[Detection of epidermal growth factor receptor gene mutations in non-small cell lung cancers by real-time polymerase chain reaction using scorpion amplification refractory mutation system].

Jing Zhang1, Zhi-Yong Liang, Xuan Zeng, Sha-Fei Wu, Jie Gao, Tong-Hua Liu.   

Abstract

OBJECTIVE: To investigate mutations of EGFR gene in non-small cell lung cancers (NSCLC) using scorpions amplification refractory mutation system (Scorpions ARMS) is in comparing the detection sensitivity with that by PCR-direct sequencing method, and in addition to study the correlation between the mutations and the clinicopathological characteristics of the patients.
METHODS: Tumor cells were collected by microdissection from paraffin embedded tumor specimens and adjacent normal lung tissues of 82 NSCLC patients. The genomic DNA was extracted. Mutations of EGFR gene (exons 18, 19, 20 and 21) were detected by PCR-direct sequencing and Scorpions ARMS methods respectively.
RESULTS: Somatic mutations were identified involving the tyrosine kinase domain of the EGFR gene in 42 of 82 cases with a mutation detection rate of 51.2% by Scorpions ARMS assay. In-frame deletions of exon 19 occurred in 20 patients and point mutation occurred at codon 858, 861 (exon 21) in 18 and 1 patients respectively. Two patients had insertions mutations and 1 patient had point mutation occurring at codon 768 (exon 20). Among the 58 informative cases analyzed by PCR-direct sequencing, 25 mutations (detection rate of 30.5%) were identified. In-frame deletions of exon 19 occurred in 13 patients and point mutation occurred at codon 858, 861 (exon 21) in 10 and 1 patients respectively. In addition, 1 patient had point mutation at codon 768 (exon 20). Overall, Scorpions ARMS assay was more sensitive in detecting mutations of EGFR than PCR-direct sequencing.
CONCLUSIONS: A higher incidence of somatic mutations of EGFR gene was detected in NSCLC of Chinese patients. Mutations were more common in female, non-smoking patients with adenocarcinoma and bronchioloalveolar carcinoma histology. Scorpions ARMS method is quicker, more sensitive and accurate in detecting the EGFR gene mutations and should provide important therapeutic and prognostic information to the clinicians.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18956645

Source DB:  PubMed          Journal:  Zhonghua Bing Li Xue Za Zhi        ISSN: 0529-5807


  6 in total

1.  EGFR mutations in patients with non-small cell lung cancer from mainland China and their relationships with clinicopathological features: a meta-analysis.

Authors:  Shuai Wang; Zhou Wang
Journal:  Int J Clin Exp Med       Date:  2014-08-15

2.  Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas.

Authors:  Zhiyong Liang; Jing Zhang; Xuan Zeng; Jie Gao; Shafei Wu; Tonghua Liu
Journal:  BMC Cancer       Date:  2010-07-19       Impact factor: 4.430

3.  Mortality outcomes of low-dose computed tomography screening for lung cancer in urban China: a decision analysis and implications for practice.

Authors:  Zixing Wang; Wei Han; Weiwei Zhang; Fang Xue; Yuyan Wang; Yaoda Hu; Lei Wang; Chunwu Zhou; Yao Huang; Shijun Zhao; Wei Song; Xin Sui; Ruihong Shi; Jingmei Jiang
Journal:  Chin J Cancer       Date:  2017-07-14

4.  Comparison of direct sequencing and amplification refractory mutation system for detecting epidermal growth factor receptor mutation in non-small-cell lung cancer patients: a systematic review and meta-analysis.

Authors:  Qi Feng; Zu-Yao Yang; Jia-Tong Zhang; Jin-Ling Tang
Journal:  Oncotarget       Date:  2017-07-08

Review 5.  [The detection methods of EGFR mutations in non-small cell lung cancer].

Authors:  Xinyu Zhang; Guiyang Liu; Xiaoguang Zhu; Weilan Wang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2011-03

6.  Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib.

Authors:  Fei Xu; Jingxun Wu; Cong Xue; Yuanyuan Zhao; Wei Jiang; Liping Lin; Xuan Wu; Yachao Lu; Hua Bai; Jiasen Xu; Guanshan Zhu; Li Zhang
Journal:  Onco Targets Ther       Date:  2012-12-12       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.